CDRH’s Division of Cardiovascular Devices Starts 30-Day Notice Reviews
This article was originally published in The Gray Sheet
Executive Summary
The division officially began taking over reviews of 30-day manufacturing notices from the Office of Compliance Feb. 1 as part of a larger reorganization.
You may also be interested in...
ODE Reorganization Reduces Reviewer-To-Manager Ratio
A restructuring in the Office of Device Evaluation, incorporating dozens of new hires, is intended to reduce the number of reviewers reporting to each manager. It took effect last week.
FDA Manufacturing-Change Reviews Will Shift From Compliance Office To ODE
The move is in line with the agency’s intention to focus on the total product life-cycle, such that the same staffers that review an original marketing submission will look at the safety and effectiveness of manufacturing changes.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”